CXCR3 and acute graft versus host disease: Compared to the use of CCR5 or CXCR3 antagonists alone, the combined blockade of these two chemokine receptor antagonists more effectively reduced the incidence of acute GVHD and alleviated the clinical manifestations of acute GVHD in mice (121).